JP2005505504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505504A5 JP2005505504A5 JP2002590906A JP2002590906A JP2005505504A5 JP 2005505504 A5 JP2005505504 A5 JP 2005505504A5 JP 2002590906 A JP2002590906 A JP 2002590906A JP 2002590906 A JP2002590906 A JP 2002590906A JP 2005505504 A5 JP2005505504 A5 JP 2005505504A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- independently
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 48
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 108020004459 Small Interfering RNA Proteins 0.000 claims 34
- 239000002924 silencing RNA Substances 0.000 claims 34
- -1 amino, substituted amino Chemical group 0.000 claims 27
- 239000000126 substance Substances 0.000 claims 26
- 108020004707 nucleic acids Proteins 0.000 claims 25
- 125000003107 substituted aryl group Chemical group 0.000 claims 24
- 150000007523 nucleic acids Chemical class 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 239000002777 nucleoside Substances 0.000 claims 21
- 125000006239 protecting group Chemical group 0.000 claims 21
- 229910052717 sulfur Inorganic materials 0.000 claims 21
- 125000000547 substituted alkyl group Chemical group 0.000 claims 20
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 19
- 229920000272 Oligonucleotide Polymers 0.000 claims 18
- 150000003904 phospholipids Chemical class 0.000 claims 18
- 150000001413 amino acids Chemical group 0.000 claims 16
- 150000002632 lipids Chemical class 0.000 claims 16
- 239000002773 nucleotide Substances 0.000 claims 16
- 125000003729 nucleotide group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 9
- 235000000346 sugar Nutrition 0.000 claims 9
- 239000003937 drug carrier Substances 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 239000011574 phosphorus Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 229940067631 Phospholipids Drugs 0.000 claims 5
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 229920002395 Aptamer Polymers 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 230000000692 anti-sense Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 230000002255 enzymatic Effects 0.000 claims 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 150000004676 glycans Polymers 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- 150000004804 polysaccharides Polymers 0.000 claims 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241000709661 Enterovirus Species 0.000 claims 2
- 241000991587 Enterovirus C Species 0.000 claims 2
- 229960000304 Folic Acid Drugs 0.000 claims 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 2
- 208000006572 Human Influenza Diseases 0.000 claims 2
- 206010022000 Influenza Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 2
- 229940088594 Vitamin Drugs 0.000 claims 2
- 229940045997 Vitamin A Drugs 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- 241000710886 West Nile virus Species 0.000 claims 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 201000005216 brain cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000005515 coenzyme Substances 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 125000005159 cyanoalkoxy group Chemical group 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 125000001165 hydrophobic group Chemical group 0.000 claims 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229960003471 retinol Drugs 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 229930003231 vitamins Natural products 0.000 claims 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N Galactosamine Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-ACETYL-D-GALACTOSAMINE Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000005256 alkoxyacyl group Chemical group 0.000 claims 1
- 125000005257 alkyl acyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 238000006065 biodegradation reaction Methods 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
Claims (58)
- R1が酸不安定性保護基である,請求項1,5または8のいずれかに記載の化合物。
- 請求項1記載の化合物を薬学的に許容しうる担体中に含む医薬組成物。
- 請求項2記載の化合物を薬学的に許容しうる担体中に含む医薬組成物。
- 請求項3記載の化合物を薬学的に許容しうる担体中に含む医薬組成物。
- 請求項4記載の化合物を薬学的に許容しうる担体中に含む医薬組成物。
- 請求項6記載の化合物を薬学的に許容しうる担体中に含む医薬組成物。
- 請求項7記載の化合物を薬学的に許容しうる担体中に含む医薬組成物。
- 患者において癌を治療する方法であって,前記患者の細胞を前記治療に適した条件下で請求項10−15のいずれかに記載の医薬組成物と接触させることを含む方法。
- 前記治療に適した条件下で1またはそれ以上の他の薬剤療法を使用することをさらに含む,請求項16記載の方法。
- 前記癌が,乳癌,肺癌,結腸直腸癌,脳癌,食道癌,胃癌,膀胱癌,膵臓癌,子宮頚癌,頭頚部癌,卵巣癌,黒色腫,リンパ腫,神経膠腫,または多剤耐性癌である,請求項16記載の方法。
- ウイルスに感染した患者を治療する方法であって,前記患者の細胞を前記治療に適した条件下で請求項10−15のいずれかに記載の医薬組成物と接触させることを含む方法。
- 前記治療に適した条件下で1またはそれ以上の他の薬剤療法を使用することをさらに含む,請求項19記載の方法。
- 前記ウイルスが,HIV,HBV,HCV,CMV,RSV,HSV,ポリオウイルス,インフルエンザ,ライノウイルス,西ナイル熱ウイルス,エボラウイルス,口蹄疫ウイルス,およびパピローマウイルスである,請求項19記載の方法。
- 請求項22記載の化合物を薬学的に許容しうる担体中に含む医薬組成物。
- 癌患者を治療する方法であって,前記患者の細胞を前記治療に適した条件下で請求項23に記載の医薬組成物と接触させることを含む方法。
- 式52:
を有する化合物。 - 式53:
を有する化合物。 - 式55:
を有する化合物。 - 式59:
を有する化合物を含む]
を有する化合物。 - 式92:
を有する化合物。 - 式66:
を有する化合物。 - 式87:
を有する化合物。 - 式94:
を有する化合物。 - 請求項25−51のいずれかに記載の化合物を薬学的に許容しうる担体中に含む医薬組成物。
- 患者において癌を治療する方法であって,前記患者の細胞を前記治療に適した条件下で請求項52記載の医薬組成物と接触させることを含む方法。
- 前記治療に適した条件下で1またはそれ以上の他の薬剤療法を使用することをさらに含む,請求項53記載の方法。
- 前記癌が,乳癌,肺癌,結腸直腸癌,脳癌,食道癌,胃癌,膀胱癌,膵臓癌,子宮頚癌,頭頚部癌,卵巣癌,黒色腫,リンパ腫,神経膠腫,または多剤耐性癌である,請求項53記載の方法。
- ウイルスに感染した患者を治療する方法であって,前記患者の細胞を前記治療に適した条件下で請求項52記載の医薬組成物と接触させることを含む方法。
- 前記治療に適した条件下で1またはそれ以上の他の薬剤療法を使用することをさらに含む,請求項56記載の方法。
- 前記ウイルスが,HIV,HBV,HCV,CMV,RSV,HSV,ポリオウイルス,インフルエンザ,ライノウイルス,西ナイル熱ウイルス,エボラウイルス,口蹄疫ウイルス,およびパピローマウイルスである,請求項56記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29221701P | 2001-05-18 | 2001-05-18 | |
US30688301P | 2001-07-20 | 2001-07-20 | |
US31186501P | 2001-08-13 | 2001-08-13 | |
US36201602P | 2002-03-06 | 2002-03-06 | |
PCT/US2002/015876 WO2002094185A2 (en) | 2001-05-18 | 2002-05-17 | Conjugates and compositions for cellular delivery |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008332136A Division JP2009149652A (ja) | 2001-05-18 | 2008-12-26 | 細胞デリバリーのためのコンジュゲートおよび組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005505504A JP2005505504A (ja) | 2005-02-24 |
JP2005505504A5 true JP2005505504A5 (ja) | 2005-09-02 |
JP4358521B2 JP4358521B2 (ja) | 2009-11-04 |
Family
ID=27501563
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002590906A Expired - Fee Related JP4358521B2 (ja) | 2001-05-18 | 2002-05-17 | 細胞デリバリーのためのコンジュゲートおよび組成物 |
JP2008332136A Withdrawn JP2009149652A (ja) | 2001-05-18 | 2008-12-26 | 細胞デリバリーのためのコンジュゲートおよび組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008332136A Withdrawn JP2009149652A (ja) | 2001-05-18 | 2008-12-26 | 細胞デリバリーのためのコンジュゲートおよび組成物 |
Country Status (6)
Country | Link |
---|---|
EP (3) | EP3231445A1 (ja) |
JP (2) | JP4358521B2 (ja) |
AU (2) | AU2002316135B9 (ja) |
CA (1) | CA2447161A1 (ja) |
HK (1) | HK1244675A1 (ja) |
WO (1) | WO2002094185A2 (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20030166512A1 (en) * | 2002-02-13 | 2003-09-04 | Medbridge, Inc. | Protein carrier system for therapeutic oligonucleotides |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US7790867B2 (en) | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
US7696334B1 (en) | 2002-12-05 | 2010-04-13 | Rosetta Genomics, Ltd. | Bioinformatically detectable human herpesvirus 5 regulatory gene |
US20040167090A1 (en) * | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
US8796436B2 (en) | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
EP2664672A1 (en) | 2003-04-17 | 2013-11-20 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
AU2012202250B2 (en) * | 2003-04-17 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
EP3222294A1 (en) * | 2003-04-30 | 2017-09-27 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
EP2402089A1 (en) | 2003-07-31 | 2012-01-04 | Handylab, Inc. | Processing particle-containing samples |
US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US20050136437A1 (en) * | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
US9045739B2 (en) | 2004-01-16 | 2015-06-02 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Immunokinases |
US7674778B2 (en) * | 2004-04-30 | 2010-03-09 | Alnylam Pharmaceuticals | Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine |
US8852862B2 (en) | 2004-05-03 | 2014-10-07 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
CA2566519C (en) | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7795419B2 (en) | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
WO2006133099A2 (en) * | 2005-06-03 | 2006-12-14 | The Cbr Institute For Biomedical Research, Inc. | Sirna microbicides for preventing and treating viral diseases |
JP2009504803A (ja) | 2005-08-22 | 2009-02-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Tlrアゴニスト |
EP1800695A1 (en) | 2005-12-21 | 2007-06-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immuno-RNA-constructs |
US11806718B2 (en) | 2006-03-24 | 2023-11-07 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US10900066B2 (en) | 2006-03-24 | 2021-01-26 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
EP2001990B1 (en) | 2006-03-24 | 2016-06-29 | Handylab, Inc. | Integrated system for processing microfluidic samples, and method of using same |
US8883490B2 (en) | 2006-03-24 | 2014-11-11 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US7998708B2 (en) | 2006-03-24 | 2011-08-16 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
ES2564303T3 (es) * | 2006-04-07 | 2016-03-21 | Idera Pharmaceuticals, Inc. | Compuestos de ARN inmunomodulador estabilizado (SIMRA) para TLR7 y TLR8 |
CN101790380B (zh) | 2007-02-07 | 2013-07-10 | 加利福尼亚大学董事会 | 合成tlr激动剂的缀合物及其应用 |
EP2609934A1 (en) | 2007-02-16 | 2013-07-03 | KTB Tumorforschungsgesellschaft mbH | Receptor And Antigen Targeted Prodrug |
WO2008131419A2 (en) | 2007-04-23 | 2008-10-30 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
US8287820B2 (en) | 2007-07-13 | 2012-10-16 | Handylab, Inc. | Automated pipetting apparatus having a combined liquid pump and pipette head system |
US8105783B2 (en) | 2007-07-13 | 2012-01-31 | Handylab, Inc. | Microfluidic cartridge |
US8182763B2 (en) | 2007-07-13 | 2012-05-22 | Handylab, Inc. | Rack for sample tubes and reagent holders |
EP3741869A1 (en) | 2007-07-13 | 2020-11-25 | Handylab, Inc. | Polynucleotide capture materials and methods of using same |
US9186677B2 (en) | 2007-07-13 | 2015-11-17 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
EP2231195B1 (en) | 2007-12-04 | 2017-03-29 | Arbutus Biopharma Corporation | Targeting lipids |
US8507455B2 (en) | 2007-12-04 | 2013-08-13 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
EP2488210A4 (en) | 2009-10-12 | 2014-04-30 | Smith Holdings Llc | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS |
US20120035362A1 (en) * | 2010-08-03 | 2012-02-09 | Berry And Associates, Inc. | Phosphoramidite derivatives of folic acid |
KR20130137160A (ko) | 2010-08-24 | 2013-12-16 | 머크 샤프 앤드 돔 코포레이션 | 내부의 비-핵산 스페이서를 함유하는 단일-가닥 RNAi 작용제 |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
CA3082652A1 (en) | 2011-04-15 | 2012-10-18 | Becton, Dickinson And Company | Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection |
WO2013067202A1 (en) | 2011-11-04 | 2013-05-10 | Handylab, Inc. | Polynucleotide sample preparation device |
AU2013231638B2 (en) | 2012-03-16 | 2017-10-12 | Merck Patent Gmbh | Targeting aminoacid lipids |
NZ630990A (en) | 2012-03-16 | 2016-04-29 | Merck Patent Gmbh | Aminoacid lipids |
CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
CN102875610A (zh) * | 2012-09-19 | 2013-01-16 | 淮海工学院 | 一种制备2-乙酰氨基-2-脱氧-3,4,6-三乙酰-β-D-氯代吡喃葡糖的方法 |
KR101392973B1 (ko) | 2012-10-15 | 2014-05-09 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
RU2653438C2 (ru) | 2012-11-15 | 2018-05-08 | Рош Инновейшен Сентер Копенгаген А/С | Конъюгаты олигонуклеотидов |
KR20170068469A (ko) | 2014-10-10 | 2017-06-19 | 에프. 호프만-라 로슈 아게 | GalNAc 포스포라미다이트, 그의 핵산 컨쥬게이트 및 그의 용도 |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
CN109069529B (zh) | 2016-03-07 | 2021-08-20 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
WO2017178656A1 (en) | 2016-04-14 | 2017-10-19 | Roche Innovation Center Copenhagen A/S | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
WO2018013999A1 (en) | 2016-07-15 | 2018-01-18 | Am Chemicals Llc | Non-nucleosidic solid supports and phosphoramidite building blocks for oligonucleotide synthesis |
CN116942841A (zh) | 2016-09-02 | 2023-10-27 | 箭头药业股份有限公司 | 靶向配体 |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
AR114551A1 (es) | 2018-08-13 | 2020-09-16 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO |
CN114364404A (zh) * | 2019-04-11 | 2022-04-15 | 东北大学 | 寡核苷酸-聚合物多手臂偶联物以及使用方法 |
CN110070506B (zh) * | 2019-04-15 | 2022-07-19 | 武汉大学 | 一种基于多尺度混合指数模型的视频去雨方法 |
WO2021101475A1 (en) * | 2019-11-21 | 2021-05-27 | Gaziantep Universitesi Rektorlugu | Synthesis and improvement of a nucleoside analogue as an anti-cancer and anti-viral drug |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
CN114767685B (zh) * | 2022-04-25 | 2023-10-20 | 北京大学第三医院(北京大学第三临床医学院) | 四氢叶酸在抑菌或者预防或治疗眼部疾病中的用途 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IS1355B6 (is) * | 1984-11-12 | 1989-04-19 | Lister Institute Of Preventive Medicine | Fjölkjarna kannar |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
CA1339303C (en) | 1987-09-21 | 1997-08-19 | Lyle John Arnold Jr. | Non-nucleotide linking reagents for nucleotide probes |
CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
JP3058686B2 (ja) | 1989-08-31 | 2000-07-04 | シティ・オブ・ホープ | キメラdna―rna触媒活性配列 |
US6168778B1 (en) | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
CA2093664C (en) | 1990-10-12 | 2003-07-29 | Fritz Eckstein | Modified ribozymes |
DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
AU679525B2 (en) | 1992-12-04 | 1997-07-03 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
EP1195442A3 (en) | 1992-12-04 | 2002-07-31 | Innovir Laboratories, Inc. | Ribozyme amplified diagnostics |
JP4117901B2 (ja) * | 1993-05-21 | 2008-07-16 | アメリカ合衆国 | デオキシヌクレオチド合成の阻害剤を使用することによって逆転写酵素依存ウイルスの複製を阻害する新規な方法 |
US5871914A (en) | 1993-06-03 | 1999-02-16 | Intelligene Ltd. | Method for detecting a nucleic acid involving the production of a triggering RNA and transcription amplification |
ES2186690T3 (es) | 1993-09-02 | 2003-05-16 | Ribozyme Pharm Inc | Acido nucleico enzimatico que contiene no-nucleotidos. |
US5861288A (en) | 1993-10-18 | 1999-01-19 | Ribozyme Pharmaceuticals, Inc. | Catalytic DNA |
EP0725788B1 (en) | 1993-10-27 | 1998-12-16 | Ribozyme Pharmaceuticals, Inc. | 2'-amido and 2'-peptido modified oligonucleotides |
US6093702A (en) * | 1993-12-20 | 2000-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |
US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5633133A (en) | 1994-07-14 | 1997-05-27 | Long; David M. | Ligation with hammerhead ribozymes |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
US5872241A (en) | 1995-01-25 | 1999-02-16 | The Trustees Of Columbia University In The City Of New York | Multiple component RNA catalysts and uses thereof |
DE19524515A1 (de) * | 1995-07-05 | 1997-01-09 | Deutsches Krebsforsch | Saccharid-Konjugate |
DE69637256T2 (de) | 1996-01-16 | 2008-06-19 | Sirna Therapeutics, Inc., Boulder | Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle |
US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
AU724627B2 (en) | 1996-12-19 | 2000-09-28 | Yale University | Bioreactive allosteric polynucleotides |
JP3903392B2 (ja) | 1996-12-24 | 2007-04-11 | サーナ・セラピューティクス・インコーポレイテッド | ヌクレオシド類似体の化学合成とそのポリヌクレオチドへの導入 |
US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
AU6591798A (en) | 1997-03-31 | 1998-10-22 | Yale University | Nucleic acid catalysts |
AU7976198A (en) | 1997-06-19 | 1999-01-04 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes with extended cleavage rule |
US6395713B1 (en) * | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
US6127173A (en) | 1997-09-22 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts with endonuclease activity |
WO1999017120A1 (en) | 1997-09-26 | 1999-04-08 | Becton, Dickinson And Company | Preparing conjugates using polyethylene glycol linkers |
EP1036169A1 (en) | 1997-12-05 | 2000-09-20 | Duke University | Nucleic acid mediated rna tagging and rna revision |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
WO1999054459A2 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
AU751480B2 (en) | 1998-04-29 | 2002-08-15 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into ribozymes |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
IL126731A0 (en) | 1998-10-23 | 1999-08-17 | Intelligene Ltd | A method of detection |
WO2000026226A1 (en) | 1998-11-03 | 2000-05-11 | Yale University | Multidomain polynucleotide molecular sensors |
EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6020199A (en) * | 1999-07-21 | 2000-02-01 | Isis Pharmaceuticals Inc. | Antisense modulation of PTEN expression |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
KR20040008526A (ko) | 2002-07-18 | 2004-01-31 | 주식회사 하이닉스반도체 | 플래시 메모리 셀의 소거 방법 |
US8240498B2 (en) | 2006-10-31 | 2012-08-14 | Crown Packaging Technology, Inc. | Resealable closure |
US9301511B1 (en) | 2015-05-05 | 2016-04-05 | Harold Edward Clarambeau | Fishing rig with floatation device |
-
2002
- 2002-05-17 EP EP17000268.7A patent/EP3231445A1/en not_active Ceased
- 2002-05-17 EP EP02746413A patent/EP1572067A4/en not_active Withdrawn
- 2002-05-17 AU AU2002316135A patent/AU2002316135B9/en not_active Ceased
- 2002-05-17 EP EP11184529.3A patent/EP2415486B1/en not_active Expired - Lifetime
- 2002-05-17 JP JP2002590906A patent/JP4358521B2/ja not_active Expired - Fee Related
- 2002-05-17 WO PCT/US2002/015876 patent/WO2002094185A2/en active Application Filing
- 2002-05-20 CA CA002447161A patent/CA2447161A1/en not_active Abandoned
-
2008
- 2008-12-26 JP JP2008332136A patent/JP2009149652A/ja not_active Withdrawn
-
2009
- 2009-02-10 AU AU2009200497A patent/AU2009200497A1/en not_active Abandoned
-
2018
- 2018-03-22 HK HK18103997.7A patent/HK1244675A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005505504A5 (ja) | ||
CN1120707C (zh) | 增强生物分子的细胞摄取的配体 | |
EP2844662B1 (en) | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | |
ES2822584T3 (es) | Inducción de dinucleótidos cíclicos del interferón tipo I | |
US6534639B1 (en) | Guanidinium functionalized oligonucleotides and method/synthesis | |
US11713340B2 (en) | Divalent nucleobase compounds and uses therefor | |
ES2605618T3 (es) | ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN | |
AU698210B2 (en) | Polyamide-oligonucleotide derivatives, their preparation and use | |
JP2015529073A5 (ja) | ||
Roviello et al. | Nucleobase-containing peptides: an overview of their characteristic features and applications | |
EA034605B1 (ru) | Новые лиганды rig-i и способы их получения | |
US11357865B2 (en) | Compositions containing nucleic acid nanoparticles with modular functionality | |
US7713944B2 (en) | Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells | |
US20230382941A1 (en) | Spherical nucleic acids with dendritic ligands | |
JP2021506312A (ja) | 鋳型指向性の核酸標的化合物 | |
TW202227135A (zh) | 用於遞送治療劑之脂質結合物 | |
JP2011511776A (ja) | RNA干渉のためのカチオン性siRNA、合成及び使用 | |
Eritja | Solid-phase synthesis of modified oligonucleotides | |
de la Torre et al. | Synthesis of Oligonucleotides Carrying Anchoring Groups and Their Use in the Preparation of Oligonucleotide–Gold Conjugates | |
US7038037B2 (en) | Method for sequential support-bound synthesis of conjugated oligomeric compounds | |
Aviñó et al. | Synthesis of Oligonucleotide–Peptide Conjugates for Biomedical and Technological Applications | |
US20160016989A1 (en) | Synthetic Polymers Containing Amino Acid Side Chains | |
Eritja Casadellà | Solid-phase synthesis of modified oligonucleotides | |
US7442788B2 (en) | Antisense molecules and method of controlling expression of gene function by using the same | |
US6872809B2 (en) | Nucleoside derivatives |